4th May 2006 07:01
Tepnel Life Sciences PLC04 May 2006 Tepnel Life Sciences plc ('Tepnel' or 'the Company') Tepnel appointed preferred supplier to AstraZeneca for DNA extraction services Manchester, UK, 04 May, 2006 - Tepnel Life Sciences PLC (AIM: TED), the UK-basedinternational Molecular Diagnostics and Research Products & Services group,announced today it has signed a global Master Services Agreement withAstraZeneca, one of the world's leading pharmaceutical companies. Under theterms of this agreement Tepnel has been appointed as a preferred supplier toAstraZeneca for DNA extraction services. By continuing to provide a high qualityservice in the market Tepnel will have the opportunity to compete for furtherbusiness and AstraZeneca will benefit from volume-related discounts. Ben Matzilevich, CEO, commented: "Following our recent positive preliminaryfinancial results for 2005 we are delighted at being able to announce more goodnews. AstraZeneca is already a valued client that has been working with us for anumber of years and this agreement is proof of the high level of client serviceand technical expertise that we are able to deliver. This agreement furtherstrengthens Tepnel's position in the pharmaceutical industry as one of Europe'slargest providers of DNA extraction services." - ends - Enquiries: For Further Information: Tepnel Life Sciences plcBen Matzilevich, CEO0161 946 2200 De Facto CommunicationsRichard Anderson020 7861 3838 Notes to Editors About Tepnel Life Sciences plc Tepnel is a UK-based international life sciences company focused on moleculardiagnostics and research products and services including DNA purification kitsand reagents, scientific services for nucleic acid purification, drug analysis,genotyping and genetically modified foods. Tepnel was founded in 1992 to exploitDNA technology generated at UMIST (University of Manchester Institute of Scienceand Technology) and is quoted on the AIM market of the London Stock Exchange(AIM: TED). More information on Tepnel can be found at www.tepnel.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
TED.LAstrazeneca